Patient Derived Xenografts/PDX Models Market Research And Global Forecast Report 2025-2030

(MENAFN- GlobeNewsWire - Nasdaq) The PDX model market is projected to grow from USD 0.37 billion in 2025 to USD 0.66 billion by 2030, with a CAGR of 12.5%. This growth is fueled by rising cancer incidences and demand for preclinical models replicating human tumor biology. Orthotopic implantation is expected to record the highest growth due to its ability to mimic natural tumor environments. The US is set to lead due to strong research infrastructure and high cancer prevalence. The gastrointestinal tumor model holds the largest market share, driven by a high incidence of GI cancers. Key players include JSR Corporation, WuXi AppTec, The Jackson Laboratory, and more.

Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) - Global Forecast to 2030" has been added to ResearchAndMarkets's offering.

The global patient-derived xenograft (PDX) model market is forecasted to grow from USD 0.37 billion in 2025 to USD 0.66 billion by 2030, driven by a CAGR of 12.5%.

The report details product development, market expansion opportunities, and provides a thorough competitive assessment of key players, including BioDuro (US) and Aragen Life Sciences (India). This extensive coverage aids in understanding market dynamics and positioning business strategies accordingly.

The demand for PDX models in oncology research, due to their effectiveness in replicating human tumor biology, remains a primary driving force. These models are pivotal in assessing drug efficacy, identifying biomarkers, and informing personalized treatment strategies. The integration of advanced technologies like next-generation sequencing with PDX platforms is further enhancing their utility. However, factors such as high costs, development time, and ethical concerns pose challenges to widespread adoption.

Orthotopic Implantation Segment Growth

The orthotopic implantation method is anticipated to register the highest CAGR during the forecast period. Its superiority in mimicking the natural tumor environment, through exact representation of tumor-stroma interactions, and disease progression contributes to its high demand. Orthotopic models provide improved translational relevance and predictive accuracy, proving beneficial in evaluating drug efficacy and resistance.

With the increasing emphasis on targeted therapies and immunotherapies, the demand for orthotopic models has surged. Advances in imaging and microsurgical techniques have improved reproducibility, making these models widely accessible for preclinical studies. The collective advantages drive this segment's growth globally.

Gastrointestinal Tumor Model Market Dominance

The gastrointestinal tumor model segment holds the largest market share, owing to the prevalence of GI malignancies, such as colorectal and gastric cancers. These models offer faithful preservation of tumor heterogeneity, making them invaluable in therapeutic evaluation. The rise in precision medicine and focused clinical trials on GI cancers bolster the demand for these robust models.

Continual improvements in engraftment techniques and molecular profiling enhance the effectiveness of gastrointestinal PDX models, maintaining their dominant market position.

U.S. Market Growth

The United States is positioned to experience the highest growth rate in the PDX model market. This growth is underpinned by the presence of leading pharmaceutical enterprises, substantial research infrastructure, and vigorous oncology research initiatives. The drive towards personalized medicine and increasing cancer prevalence contribute significantly to the growing demand for PDX models.

Moreover, extensive investment in translational research, combined with collaborative efforts between academia and industry, propels market expansion. Supportive regulatory frameworks and advanced laboratory facilities further enhance the U.S. market's strength in this sector.

Key Companies and Research Coverage

Leading companies in the PDX model market include JSR Corporation (Japan), WuXi AppTec (China), The Jackson Laboratory (US), Charles River Laboratories (US), and Taconic Biosciences, Inc. (US). This research report categorizes the market by implantation method, type, tumor type, application, end-user, and region.

The report comprehensively analyzes the drivers, restraints, challenges, and opportunities influencing market growth. It provides insights on strategic initiatives and new product launches by key industry players. Further, a competitive assessment includes a detailed evaluation of leading market players and emerging startups.

Key Attributes:

Report Attribute	Details
No. of Pages	367
Forecast Period	2025 - 2030
Estimated Market Value (USD) in 2025	$0.37 Billion
Forecasted Market Value (USD) by 2030	$0.66 Billion
Compound Annual Growth Rate	12.5%
Regions Covered	Global

Market Dynamics

Drivers

• Growing Demand for Immuno-Oncology and Complex Biologics
• Rising Preference for Humanized Pdx Models
• Focus on Government-Funded Initiatives for Cancer Research

Challenges

• Limitations of Humanized Mouse Models

Opportunities

• Increasing Preference for Personalized Medicines in Oncology
• Growing Demand for Cdx Models for Pdx Model Vendors

Industry Trends

• Porter's Five Forces Analysis
• Ecosystem Analysis
• Value Chain Analysis
• Pricing Analysis
• Macroeconomic Outlook
• Investment & Funding Scenario
• Patent Analysis

Case Studies

• Imaging-Ready Orthotopic Pdx for Pediatric Brain Tumors
• Host-Strain Selection Using Breast Cancer Pdx
• Resistance-Anchored Pdx Panel to Design Mouse Clinical Trial

Company Profiles

• Charles River Laboratories
• The Jackson Laboratory
• Inotiv
• Jsr Corporation
• Genoway
• Wuxi Apptec + Wuxi Biologics
• Biocytogen Pharmaceuticals Co. Ltd.
• Taconic Biosciences, Inc.
• Oncodesign Services (Oncodesign Precision Medicine)
• Champions Oncology, Inc.
• Pharmaron
• Syngene International Limited
• Labcorp
• Eurofins Scientific
• Vitalstar Biotechnology Co. Ltd.
• Creative Animodel
• Joinn Laboratories (China) Co. Ltd.
• Creative Biolabs
• Aragen Life Sciences Ltd.
• Pharmtest Services
• Lide Shanghai Biotech Co. Ltd.
• Certis Oncology Solutions
• Innoser
• Shanghai Chempartner
• Ivrs Ab

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Patient Derived Xenografts/PDX Models Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN25022026004107003653ID1110787833